Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
BRD4 Inhibitor-20
Contact us for more batch information
BRD4 Inhibitor-20
Catalog No. T61318Cas No. 2490311-14-1
BRD4 Inhibitor-20 is a potent bromodomain protein 4 (BRD4) inhibitor with oral activity. BRD4 Inhibitor-20 has antiproliferative activity in cancer cell lines and is used in studies of various cancers, such as colon cancer.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $38 | In Stock | |
| 5 mg | $93 | In Stock | |
| 10 mg | $153 | In Stock | |
| 25 mg | $297 | In Stock | |
| 50 mg | $448 | In Stock | |
| 100 mg | $630 | In Stock | |
| 500 mg | $1,240 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $117 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "BRD4 Inhibitor-20"
MI-538
T160721857417-10-7
MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM).
- $97
Size
QTY
IACS-9571
T115971800477-30-8
IACS-9571 is a selective and potent inhibitor of TRIM24 and BRPF1, (IC50: 8 nM for TRIM24; Kds: 31 nM and 14 nM for TRIM24 and BRPF1).
- $1,670
Size
QTY
AU-15330
T399542380274-50-8In house
AU-15330 is a protein hydrolysis-targeted chimeric (PROTAC) degrader of the SWI/SNF ATPase subunits SMARCA2 and SMARCA4.AU-15330 potently inhibits tumor growth in a prostate cancer xenograft model and acts synergistically with the AR antagonist enzalutamide.AU-15330 shows partial therapeutic efficacy and non-toxicity with the AR antagonist enzalutamide in a desmoplasia-resistant prostate cancer (CRPC) model. AU-15330 showed partial therapeutic efficacy in a denervation-resistant prostate cancer (CRPC) model and AU-15330 was characterized by non-toxicity.
- $139
Size
QTY
MG 149
T65841243583-85-8
MG 149 (Tip60 HAT inhibitor) is a selective and potent Tip60 inhibitor with IC50 of 74 uM, similar potentcy for MOF(IC50= 47 uM).
- $48
Size
QTY
dBET6
Cited
T51301950634-92-0
dBET6 is a selective and cell-permeable degrader of BET based on PROTAC (IC50: 14 nM). It has antitumor activity.
- $48
Size
QTY
CitedMZP-55
T137862010159-48-3
MZP-55 is a selective BRD3/4 degrader based on PROTAC technology(Brd4BD2 with Kd of 8 nM)
- $456
Size
QTY
SGC-SMARCA-BRDVIII
T95681997319-84-2
SGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2, SMARCA4, PB1(2), PB1(3) and PB1(5) with Kds of 35 nM, 36 nM, 3.7 μM, 2.0 μM and 13 nM, respectively.
- $39
Size
QTY
LP99
T157841808951-93-0
LP99 is an epigenetic probe. LP99 disrupts the binding of BRD7 and BRD9 to chromatin in cells. LP99 is an effective and selective inhibitor of the BRD7 and BRD9 bromodomains (Kd: 99 nM against BRD9).
- $36
Size
QTY
Pocenbrodib
T696912304372-79-8In house
Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.
- $790
Size
QTY
NI-57
TQ00831883548-89-7
NI-57 is an inhibitor of proteins of bromodomain and plant homeodomain finger-containing (BRPF) family, with IC50s of 3.1, 46 and 140 nM for BRPF1, BRPF2 (BRD1) and BRPF3, respectively.
- $34
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | BRD4 Inhibitor-20 is a potent bromodomain protein 4 (BRD4) inhibitor with oral activity. BRD4 Inhibitor-20 has antiproliferative activity in cancer cell lines and is used in studies of various cancers, such as colon cancer. |
| In vitro | BRD4 Inhibitor-20 has inhibitory activity for BRD4 (BD1) and BRD4 (BD2) with IC50 values of 19 nM and 28 nM, respectively. BRD4 Inhibitor-20 has anti-proliferation potency with IC50 values of 4.75 μM, 1.35 μM and 44.07 μM in HT-29, HL-60 and WI-38 cells, respectively[1]. |
| In vivo | Oral BRD4 Inhibitor -20, 15mg/kg showed good oral pharmacokinetic characteristics[1]. |
| Molecular Weight | 358.41 |
| Formula | C18H18N2O4S |
| Cas No. | 2490311-14-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (83.7 mM)  | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.